Our proprietary immune profiling technology provides unparalleled insight.
Atreca is creating a new class of immuno-oncology agents.
Immunotherapy is revolutionizing the treatment of cancer by engaging a patient’s own immune response to battle the disease. At the vanguard of this revolution in cancer treatment are checkpoint inhibitors and immune activators that “take the brake off” existing anti-cancer immune responses to allow those responses to kill tumor cells. Unfortunately, many patients do not have robust anti-cancer immune responses to harness, resulting in sub-optimal clinical responses to those therapeutics. These drugs also have side effects that limit treatment in some patients. Understanding how the immune system drives clinical response is crucial for targeting these therapeutics more effectively and for developing novel treatment regimens and combination therapies to drive greater efficacy and better clinical outcomes.
Atreca’s proprietary Immune Repertoire Capture™ (IRC™) technology delivers high-fidelity data from the active and clinically productive anti-cancer immune responses of patients who respond well to checkpoint inhibition or other immuno-modulatory treatments. IRC™ technology generates the sequences of functional, native antibodies and T cell receptors (TCRs) from select single human B and T cells, respectively, at high-throughput with virtually no bias or error. By analyzing these quantitative data, such robust anti-cancer immune responses are mined to generate biotherapeutics that provide the “engine and steering” in combination with checkpoint inhibitors and immune activators, driving anti-cancer immune responses more robustly and specifically to improve treatment outcomes in the larger group of cancer patients who fail to respond well to checkpoint inhibitor therapy or who have a relapse of their cancer. Atreca therapeutics will drive better outcomes in more cancer patients in combination with checkpoint inhibitors or immune activators.
CASE STUDY – Checkpoint Inhibition Stimulates Key Changes in Antibody Expression
Atreca’s IRC™ has identified key changes in B cells in patients who have had strong responses to treatment with anti-PD1 therapy. In the illustration below, red color indicates new clonal families of antibodies generated in one patient. Representatives of these new clonal families were found to bind novel cancer antigens and modulate antibody dependent cellular cytotoxicity (ADCC) killing of cancer cells.
Based on this research, the Company is continuing to profile the immune repertoires of cancer patients to identify the antibodies and antigens that are driving productive anti-tumor immune responses.